Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Real-world Effectiveness of PD-(L)1 Inhibitors Alone or in Combination with Chemotherapy in First-line PDL1-high Non-squamous Lung Cancer

ESMO-Virtual-Plenaries-April-2021-1000x250
Start date
08 Apr 2021
End date
09 Apr 2021

The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.

Programme

Thursday 8 April

Welcome and introduction, Scientific background and context

Natasha Leighl, Princess Margaret Cancer Centre, Toronto, ON, Canada

Real world effectiveness of PD-(L)1 inhibitors alone or in combination with chemotherapy in first-line PDL1-high non-squamous lung cancer

Solange Peters, Centre Hospitalier Universitaire Vaudois – CHUV, Lausanne, Switzerland

Critical analysis and perspectives

Federico Cappuzzo, Istituto Nazionale Tumori Regina Elena, Rome, Italy

Live discussion and Q&A

Faculty and online audience (via chat feature)

Friday 9 April

Webcast of the ESMO Virtual Plenary plus additional live Discussion and Q&A with Faculty and online audience (via chat feature)

Solange Peters, Centre Hospitalier Universitaire Vaudois – CHUV, Lausanne, Switzerland 

Federico Cappuzzo, Istituto Nazionale Tumori Regina Elena, Rome, Italy 

Tony SK Mok, Prince of Wales Hospital, Hong Kong, China

Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea

Daniel Tan, National Cancer Centre Singapore, Singapore

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings